Missed GME or NVDA? Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
TGTX Stock Forecast 2025-2026
$41.33
Current Price
$6.49B
Market Cap
Buy 7
Hold 0
Sell 1
Wall St Analyst Ratings
Distance to TGTX Price Targets
+33.1%
To High Target of $55.00
+16.1%
To Median Target of $48.00
-73.4%
To Low Target of $11.00
TGTX Price Momentum
+11.8%
1 Week Change
+3.7%
1 Month Change
+206.8%
1 Year Change
+37.3%
Year-to-Date Change
-4.6%
From 52W High of $43.32
+219.6%
From 52W Low of $12.93
📉 MARKET SELLOFF ALERT
10 Quality Stocks Worth Considering Now
Researching TG Therapeutics (TGTX) after the drop? Our ex-Goldman Sachs analyst reveals if it made our list of 10 oversold quality stocks with strong growth potential.
Get our FREE market selloff report + exclusive analysis on TGTX and similar high-potential opportunities.
Latest TGTX Stock Price Targets & Analyst Predictions
Based on our analysis of 15 Wall Street analysts, TGTX has a bullish consensus with a median price target of $48.00 (ranging from $11.00 to $55.00). The overall analyst rating is Strong Buy (8.8/10). Currently trading at $41.33, the median forecast implies a 16.1% upside. This outlook is supported by 7 Buy, 0 Hold, and 1 Sell ratings.
The most optimistic forecast comes from Edward White at HC Wainwright & Co., projecting a 33.1% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
TGTX Analyst Ratings
7
Buy
0
Hold
1
Sell
TGTX Price Target Range
Low
$11.00
Average
$48.00
High
$55.00
Current: $41.33
Latest TGTX Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for TGTX.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Mar 4, 2025 | HC Wainwright & Co. | Edward White | Buy | Reiterates | $55.00 |
| Jan 15, 2025 | HC Wainwright & Co. | Edward White | Buy | Reiterates | $55.00 |
| Nov 25, 2024 | JP Morgan | Eric Joseph | Overweight | Maintains | $43.00 |
| Nov 5, 2024 | Goldman Sachs | Corinne Jenkins | Neutral | Maintains | $22.00 |
| Nov 5, 2024 | HC Wainwright & Co. | Edward White | Buy | Maintains | $55.00 |
| Oct 29, 2024 | TD Cowen | Tara Bancroft | Buy | Initiates | $50.00 |
| Sep 18, 2024 | HC Wainwright & Co. | Edward White | Buy | Reiterates | $49.00 |
| Aug 7, 2024 | Goldman Sachs | Corinne Jenkins | Neutral | Maintains | $20.00 |
| Aug 7, 2024 | B. Riley Securities | Mayank Mamtani | Buy | Maintains | $34.00 |
| Aug 6, 2024 | HC Wainwright & Co. | Edward White | Buy | Reiterates | $49.00 |
| May 2, 2024 | HC Wainwright & Co. | Edward White | Buy | Maintains | $49.00 |
| May 2, 2024 | Ladenburg Thalmann | Matthew Kaplan | Buy | Maintains | $40.00 |
| Apr 18, 2024 | JP Morgan | Eric Joseph | Overweight | Reiterates | $25.00 |
| Apr 18, 2024 | Ladenburg Thalmann | Matthew Kaplan | Buy | Reiterates | $39.00 |
| Apr 18, 2024 | HC Wainwright & Co. | Edward White | Buy | Reiterates | $45.00 |
| Mar 1, 2024 | HC Wainwright & Co. | Edward White | Buy | Reiterates | $45.00 |
| Feb 29, 2024 | Goldman Sachs | Corinne Jenkins | Neutral | Maintains | $13.00 |
| Feb 28, 2024 | HC Wainwright & Co. | Edward White | Buy | Reiterates | $45.00 |
| Feb 5, 2024 | B. Riley Securities | Mayank Mamtani | Buy | Maintains | $29.00 |
| Jan 11, 2024 | HC Wainwright & Co. | Edward White | Buy | Maintains | $45.00 |
Tg Therapeutics Inc. (TGTX) Competitors
The following stocks are similar to TG Therapeutics based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Tg Therapeutics Inc. (TGTX) Financial Data
Tg Therapeutics Inc. has a market capitalization of $6.49B with a P/E ratio of 275.5x. The company generates $329.00M in trailing twelve-month revenue with a 7.1% profit margin.
Revenue growth is +146.0% quarter-over-quarter, while maintaining an operating margin of +27.7% and return on equity of +12.2%.
Valuation Metrics
Market Cap
$6.49B
Enterprise Value
$5.95B
P/E Ratio
275.5x
PEG Ratio
42.6x
Price/Sales
19.7x
Growth & Margins
Revenue Growth (YoY)
+146.0%
Gross Margin
+85.8%
Operating Margin
+27.7%
Net Margin
+7.1%
EPS Growth
+146.0%
Financial Health
Cash/Price Ratio
+5.2%
Current Ratio
6.2x
Debt/Equity
114.4x
ROE
+12.2%
ROA
+5.8%
💰 DON'T MISS THIS OPPORTUNITY
Get All 10 Quality Stocks For This Market Selloff
Still researching investments after the market drop? Our ex-Goldman Sachs analyst has already identified the 10 highest-quality oversold stocks with strong fundamentals and upside potential.
Why spend hours researching when we've already done the work? Get instant access to our complete market selloff analysis.
Tg Therapeutics Inc. (TGTX) Business Model
About Tg Therapeutics Inc.
What They Do
Develops treatments for B-cell malignancies and autoimmune diseases.
Business Model
The company operates by developing and commercializing innovative therapies aimed at specific immune system processes related to B-cell malignancies and autoimmune diseases. It generates revenue through the advancement of its drug pipeline, focusing on conditions like chronic lymphocytic leukemia and multiple sclerosis, and leveraging partnerships to enhance its research and development capabilities.
Additional Information
Tg Therapeutics is positioned as a significant player in the biopharmaceutical sector, contributing to the growth of targeted therapies and personalized medicine. The company has a strong focus on improving patient outcomes and is actively involved in collaborations that bolster its development efforts.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
338
CEO
Mr. Michael S. Weiss Esq.
Country
United States
IPO Year
2010
Website
www.tgtherapeutics.comTg Therapeutics Inc. (TGTX) Latest News & Analysis
Latest News
Quick Summary
TG Therapeutics presented data on BRIUMVI® for relapsing multiple sclerosis at the American Academy of Neurology 2025 meeting, enhancing its visibility in the market.
Why It Matters
Positive data on BRIUMVI® for relapsing multiple sclerosis can boost TG Therapeutics' stock value, indicating strong market potential and investor confidence in product pipeline.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
TGTX reports strong adoption of Briumvi, its sole marketed product for relapsing multiple sclerosis, positively impacting revenue growth.
Why It Matters
Strong adoption of Briumvi signals robust revenue growth for TGTX, indicating potential for increased market share and profitability, which can boost investor confidence and stock performance.
Source: Zacks Investment Research
Market Sentiment:
Positive
Quick Summary
TG Therapeutics published two articles on CD20 treatments for multiple sclerosis, including findings on seven patients who switched to BRIUMVI® for better efficacy or tolerability.
Why It Matters
The publication of research on BRIUMVI® could enhance its market position, influencing sales potential and investor sentiment in TG Therapeutics. Positive findings may drive stock value.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
TG Therapeutics, Inc. (TGTX) is experiencing subdued trading, yet shares are in an uptrend with potential for continuation.
Why It Matters
Subdued trading in TG Therapeutics indicates potential volatility, but the uptrend suggests investor confidence, which may attract further interest and support share price growth.
Source: Benzinga
Market Sentiment:
Positive
Quick Summary
Root insurance stock reached a new high, showing strong performance with favorable Composite and Relative Strength Ratings as part of the IBD 50.
Why It Matters
Root's stock surge indicates strong market confidence and performance metrics, suggesting potential for continued growth and attracting investor interest in the insurance sector.
Source: Investors Business Daily
Market Sentiment:
Positive
Quick Summary
Precision Biosciences' ARCUS platform advances gene editing with strategic partnerships for azer-cel. TG Therapeutics' BRIUMVI sees sales growth, aiding future funding. DTIL rated "Buy," TGTX rated "Hold."
Why It Matters
Precision Biosciences' partnerships enhance its gene editing prospects, impacting its stock value. TG Therapeutics' sales growth boosts funding for future projects, influencing investor confidence and market performance.
Source: Seeking Alpha
Market Sentiment:
Positive
Frequently Asked Questions About TGTX Stock
What is Tg Therapeutics Inc.'s (TGTX) stock forecast for 2025?
Based on our analysis of 15 Wall Street analysts, Tg Therapeutics Inc. (TGTX) has a median price target of $48.00. The highest price target is $55.00 and the lowest is $11.00.
Is TGTX stock a good investment in 2025?
According to current analyst ratings, TGTX has 7 Buy ratings, 0 Hold ratings, and 1 Sell ratings. The stock is currently trading at $41.33. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for TGTX stock?
Wall Street analysts predict TGTX stock could reach $48.00 in the next 12 months. This represents a 16.1% increase from the current price of $41.33. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Tg Therapeutics Inc.'s business model?
The company operates by developing and commercializing innovative therapies aimed at specific immune system processes related to B-cell malignancies and autoimmune diseases. It generates revenue through the advancement of its drug pipeline, focusing on conditions like chronic lymphocytic leukemia and multiple sclerosis, and leveraging partnerships to enhance its research and development capabilities.
What is the highest forecasted price for TGTX Tg Therapeutics Inc.?
The highest price target for TGTX is $55.00 from Edward White at HC Wainwright & Co., which represents a 33.1% increase from the current price of $41.33.
What is the lowest forecasted price for TGTX Tg Therapeutics Inc.?
The lowest price target for TGTX is $11.00 from at , which represents a -73.4% decrease from the current price of $41.33.
What is the overall TGTX consensus from analysts for Tg Therapeutics Inc.?
The overall analyst consensus for TGTX is bullish. Out of 15 Wall Street analysts, 7 rate it as Buy, 0 as Hold, and 1 as Sell, with a median price target of $48.00.
How accurate are TGTX stock price projections?
Stock price projections, including those for Tg Therapeutics Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: April 28, 2025 7:09 AM UTC